|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-4-22
|
|
pubmed:abstractText |
To determine the efficacy of a three-fold reduced dose (RD, 27 mg) of intravesical bacille Calmette-Guérin (BCG) against the standard dose (81 mg) in patients with superficial bladder cancer, assessing recurrence, progression and differences in toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1464-4096
|
|
pubmed:author |
pubmed-author:ArribasSS,
pubmed-author:BernuyCC,
pubmed-author:CamachoJ EJE,
pubmed-author:CarballidoJJ,
pubmed-author:ChesaNN,
pubmed-author:De TorresJ AJA,
pubmed-author:FloresNN,
pubmed-author:GalvinAA,
pubmed-author:IsornaSS,
pubmed-author:MaderoRR,
pubmed-author:Martínez-PiñeiroJ AJA,
pubmed-author:Martínez-PiñeiroLL,
pubmed-author:MuntañolaPP,
pubmed-author:NogueiraJ LJL,
pubmed-author:PereiraII,
pubmed-author:PertusaCC,
pubmed-author:ReselLL,
pubmed-author:RiojaL ALA,
pubmed-author:SebastiánJ LJL,
pubmed-author:SolsonaEE,
pubmed-author:VelaRR,
pubmed-author:for CUETO (Club Urológico Español de Tratamiento Oncológico)
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
671-80
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11966623-Adjuvants, Immunologic,
pubmed-meshheading:11966623-Administration, Intravesical,
pubmed-meshheading:11966623-Adult,
pubmed-meshheading:11966623-Aged,
pubmed-meshheading:11966623-BCG Vaccine,
pubmed-meshheading:11966623-Cystectomy,
pubmed-meshheading:11966623-Disease Progression,
pubmed-meshheading:11966623-Disease-Free Survival,
pubmed-meshheading:11966623-Female,
pubmed-meshheading:11966623-Follow-Up Studies,
pubmed-meshheading:11966623-Humans,
pubmed-meshheading:11966623-Male,
pubmed-meshheading:11966623-Middle Aged,
pubmed-meshheading:11966623-Multivariate Analysis,
pubmed-meshheading:11966623-Neoplasm Recurrence, Local,
pubmed-meshheading:11966623-Prospective Studies,
pubmed-meshheading:11966623-Risk Factors,
pubmed-meshheading:11966623-Urinary Bladder Neoplasms
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer.
|
|
pubmed:affiliation |
Hospital La Paz, Avenida San Luis 95, 28033 Madrid, Spain. mpineiro@pulso.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
